BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 21, 2025
Home
»
Newsletters
» BioWorld
BioWorld
April 29, 2002
View Archived Issues
FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive
Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today)
Read More
Senators Want To Close Gaps In Generic Drug Legislation
Read More
Hirschsprung Disease Gene Find Is First Complete Dissection Of Multifactorial Genetic Disorder
Read More
IDEC, Seikagaku Add $34M Extension To IDEC-152 Deal
Read More
Other News To Note
Read More
BIO Names Specter, Harkin Top Legislators Of The Year
Read More
Appointments And Advancements
Read More
Quarterly Earnings Reports
Read More
